HER2-positive breast cancer registry
Part of Cancer, Skin clinical trials.
This registry tracks people with HER2-positive breast cancer to learn more about the disease and how it's treated. You can join at any stage of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be HER2-positive (a type that has a protein called HER2).
- Your cancer can be at any stage, from early (Stage I) to advanced (Stage IV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a sequence of targeted therapy drugs for HER2-positive advanced breast cancer that has spread or cannot be removed by surgery. It aims to see if starting with trastuzumab rezetecan, followed by pyrotinib and trastuzumab plus capecitabine, helps control the cancer.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This study looks at a test called HER2 IHC (a way to check for a protein called HER2 on tumor cells) in people with certain cancers: non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), gynecological cancers (cervical, endometrial, ovarian), and urothelial cancer (UC). It aims to see how well the test works in different patients. You may join if you have enough stored tumor tissue from a biopsy or surgery done within the past 5 years.
This study looks at how patients with advanced breast cancer (HER2-positive type) respond to anti-HER2 drugs over time. Researchers in Kazakhstan are reviewing medical records to understand which treatments work best and help improve care for future patients.
This study tracks how patients with HER2-positive early-stage breast cancer receive treatment and stick to their treatment plan after their care moves to local hospitals. The trial helps doctors understand whether patients follow through with their recommended therapy when treated closer to home.
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.